---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-090055"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-08-14T20:07:42+00:00"
generated_at: "2026-08-14T20:14:24.939188+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics Q2 2026 net loss $2.8M; closes Kira acquisition, $132M PIPE

## Summary
- Q2 2026 net loss $2.8M ($0.10/share); cash $7.3M at June 30, 2026.
- Closed all-stock acquisition of Kira Pharmaceuticals in July 2026.
- Raised $132M gross proceeds in PIPE co-led by Affinity and Ikarian.
- KP-104 Phase 2 interim data expected Q4 2026; briquilimab pre-BLA meeting Q1 2027.
- R&D expense $5.1M, G&A $4.1M for Q2 2026.

## SEC filing metadata
- accession: 0001213900-26-090055
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-08-14T20:07:42+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/0001213900-26-090055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/ea0302049-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-090055
- JSON: https://secwatch.observer/filing/0001213900-26-090055.json
- Plain text: https://secwatch.observer/filing/0001213900-26-090055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.